Genomic Profiling and Molecular Markers to Identify Targetable, Actionable, and Therapeutically Significant Genomic Alterations in the Setting of Lung Cancer

Genomic Profiling and Molecular Markers to Identify Targetable, Actionable, and Therapeutically Significant Genomic Alterations in the Setting of Lung Cancer is organized by CMEducation Resources, LLC.

Release Date: November 29, 2017
Expiration Date: November 29, 2019

Accreditation:
The University of Massachusetts Medical School designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credits(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Course Overview:
In this web-based program, physicians will learn how recent developments in genomic profiling have advanced the management of lung cancer.

Educational Objectives:
Upon completion of this activity, participants will be able to:

• Understand the role of NGS-based comprehensive genomic profiling fits into lung cancer management strategies
• Identify actionable mutational targets and targeted therapies across the spectrum of lung cancer
• Explain the differences-sensitivity, specificity, and utility-between hot spot panels and hybrid capture NGS comprehensive genomic profiling
• Detail how evidence-based deployment of genomic profiling can improve clinical outcomes in lung cancer
• Identify which lung cancer patient populations are appropriate candidates for NGS-based assessments and interpret and act upon results of NGS mutational testing

Additional details will be posted as soon as information is available.